723278-29-3

Upstream product

• 110295-93-7 (2-amino-thiazol-5-yl)acetic acid methyl ester 
• 385785-04-6 N’-(2-cyano-5-(3-chloropropoxy)-4-methoxyphenyl)-N,N-dimethylformamidine 
• 723278-26-0 tert-butyl 5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1,3-thiazol-2-ylcarbamate 
• 52805-34-2 4-(benzyloxy)-3-methoxybenzonitrile 
• 2426-87-1 3-methoxy-4-(phenylmethoxy)benzaldehyde 
• 385785-32-0 N-(3-fluorophenyl)-2-[2-(tritylamino)-1,3-thiazol-5-yl]acetamide 
• 385785-17-1 methyl [2-(tritylamino)-1,3-thiazol-5-yl]acetate 
• 385785-18-2 [2-(tritylamino)-1,3-thiazol-5-yl]acetic acid 
• 385784-84-9 4-(benzyloxy)-5-methoxy-2-nitrobenzonitrile 
• 385785-02-4 2-amino-4-(benzyloxy)-5-methoxybenzonitrile 
• 385785-31-9 2-(2-amino-1,3-thiazol-5-yl)-N-(3-fluorophenyl)acetamide 

Downstream Products

• 723279-41-2 N-(3-fluorophenyl)-2-{2-[(7-{3-[(2-hydroxyethyl)amino]propoxy}-6-methoxyquinazolin-4-yl)amino]-1,3-thiazol-5-yl}acetamide 
• 723279-07-0 2-(2-((7-(3-((2S)-2-((ethyl-(2-hydroxyethyl)amino)methyl)pyrrolidin-1-yl)propoxy)-6-methoxyquinazolin-4-yl)amino)-1,3-thiazol-5-yl)-N-(3-fluorophenyl) acetamide 
• 723279-62-7 2-(2-((7-(3-((2-fluoroethyl)-(2-hydroxyethyl)amino)propoxy)-6-methoxyquinazolin-4-yl)amino)-1,3-thiazol-5-yl)-N-(3-fluorophenyl)acetamide 
• 723279-79-6 N-(3-fluorophenyl)-2-(2-((7-(3-((2-hydroxyethyl)-(2-methoxyethyl)amino)propoxy)-6-methoxyquinazolin-4-yl)-amino)-1,3-thiazol-5-yl)acetamide 
• 723278-14-6 di-tert-butyl {1-[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1,3-thiazol-2-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]piperidin-4-yl}methyl phosphate 
• 385782-89-8 N-(3-fluorophenyl)-2-{2-[(7-{3-[4-(hydroxymethyl)piperidin-1-yl]propoxy}-6-methoxyquinazolin-4-yl)amino]-1,3-thiazol-5-yl}acetamide 
• 385782-93-4 N-(3-fluorophenyl)-2-{2-[(7-{3-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]propoxy}-6-methoxyquinazolin-4-yl)amino]-1,3-thiazol-5-yl}acetamide 

Relevant academic research and scientific papers

Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors

The synthesis of a novel series of quinazolines substituted at C4 by five-membered ring aminoheterocycles is reported. Their in vitro structure-activity relationships versus Aurora A and B serine-threonine kinases is discussed. Our results demonstrate tha

QUINAZOLINE COMPOUNDS

Quinazoline derivatives of formula (I) wherein A is 5-membered heteroaryl containing a sulphur atom and optionally containing one or more nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.

SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS

The use of a compound of formula (I) 1 or a salt, ester or amide thereof; where X is O, or S, S(O) or S(O)2, or NR6 where R6 is hydrogen or C1-6 alkyl,; R5 is an optionally substituted 5-membered heteroaromatic ring, R1, R2 ,R3, R4 are independently selected from various specified moieties, in the preparation of a medicament for use in the inhibition of aurora 2 kinase. Certain compounds are novel and these, together with pharmaceutical compositions containing them are also described and claimed